VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
RDY
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
RDYDr. Reddy's Laboratories Limited
$14.79$12.3B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksRDYCash Flow

Dr. Reddy's Laboratories Limited (RDY) Cash Flow Statement

26Y historyFree accessUpdated daily

Earnings quality appears increasingly strained, with cumulative 10-quarter operating cash flow of roughly $87.4B trailing net income of $111.1B by about $23.7B (0.79x OCF/NI), 2027Q1 operating cash flow turning negative at -$927M, and free cash flow margin swinging from 12.6% in 2025Q4 to 2.7% in 2027Q2 amid $21.9B of 2027 working capital consumption.

Income StatementBalance SheetCash FlowRatios

RDY Cash Flow Statement

Annual statement

RDY Cash Flow Statement

Dr. Reddy's Laboratories Limited (RDY) cash flow statement — 26-year operating, investing & financing cash flows

AnnualQuarterly
MetricTTMMar'26Mar'25Mar'24Mar'23Mar'22Mar'21Mar'20Mar'19Mar'18Mar'17Mar'16Mar'15Mar'14Mar'13Mar'12Mar'11Mar'10Mar'09Mar'08Mar'07Mar'06Mar'05Mar'04Mar'03Mar'02Mar'01
Cash from Operations30.11B56.65B46.43B45.43B58.88B28.11B35.7B29.84B28.7B18.03B21.51B41.25B25.03B19.46B13.32B16.15B8.01B13.23B4.5B6.12B11.83B1.65B2.29B4.01B4.35B4.65B614.87M
Operating CF Margin %-16.03%14.26%16.27%23.94%13.11%1397%17.09%18.66%12.69%15.28%26.66%16.89%14.73%11.45%16.69%10.72%18.82%6.49%12.24%18.13%6.77%11.77%19.92%24.17%27.99%5.62%
Operating CF Growth %-141.25%22.01%2.19%-22.83%109.46%-21.27%19.64%3.96%59.21%-16.19%-47.84%64.77%28.62%46.15%-17.54%101.65%-39.45%193.58%-26.42%-48.26%618.25%-28.11%-42.82%-7.95%-6.32%655.88%-
Net Income28.03B45.09B57.24B55.68B45.07B23.57B17.24B19.5B18.8B9.81B12.04B20.01B22.18B21.51B16.78B14.26B11.04B1.07B-5.17B4.68B9.35B1.63B211.27M2.48B3.52B4.92B739.28M
Depreciation & Amortization21.51B21.68B17.06B14.84B12.64B11.82B12.8B12.47B12.19B11.71B11.28B10.25B8.1B7.11B5.55B5.21B4.15B4.16B3.81B6.2B3.02B1.57B1.31B1.13B1.01B945.26M892.6M
Stock-Based Compensation117M0424M407M397M592M584M521M389M454M398M471M498M436M390M326M265M226M131M257.79M175.38M162.25M144M147.73B000
Deferred Taxes4.71B019.54B16.19B15.3B8.73B9.18B-1.47B3.65B4.54B2.61B7.13B5.98B5.09B4.9B4.2B1.4B985M1.17B-2.35B-1.11B-55.3M-95.59M-135.14M568.72K-268.29M19.46M
Other Non-Cash Items-1.66B2.12B-17.85B-21.5B-6.67B-2.69B6.63B6.35B-547M488M535M3.57B3.31B-4.3B-1.15B1.1B-2.11B8.33B12.82B592.61M3.46B214.37M609.41M-147.37B494.31M352.83M-46.56K
Working Capital Changes-22.28B-12.24B-29.99B-20.18B-7.86B-13.91B-10.72B-7.54B-5.77B-8.96B-5.35B-188M-15.04B-10.39B-13.15B-8.96B-6.74B-1.55B-8.27B-3.26B-3.06B-1.88B113.23M168.46M-677.77M-1.3B-1.29B
Change in Receivables1.39B-7.07B-10.28B-8.05B-5.75B-17.01B2.08B-12.45B1.8B-2.1B3.04B833M-10.9B118M2M3M-4.58B900M-7.35B226.93M151.62M33.63M79.44M19.87B93.88B00
Change in Inventory-10.49B-9.05B-12.75B-18.45B-2.65B-5.33B-12.4B-1.49B-8.5B-3.23B-6.33B-2.52B-5.45B-3.97B-3.87B-4.35B-3.62B-1.59B-1.94B-3.91B-997.71M-1.86B-514.19M-335.84M-439.57M-364.67M-298.96M
Change in Payables-7.14B2.94B00017.01B00-1.8B00000-4.5B-5.97B1.15B001.08B889.68M1.51B-763.52M690.18B584.96B00
Cash from Investing-31.03B-70.53B-58.08B-40.28B-41.37B-26.39B-22.66B-4.92B-7.73B-14.88B-18.47B-20.42B-22.9B-16.62B-13.94B-18.66B-8.66B-7B-3.47B-9.6B593.86M-34.61B632.88M-6.52B-1.95B-1.53B-686.95M
Capital Expenditures-25.73B-40.43B-27.5B-16.4B-11.32B-19.05B-9.74B-4.85B-7.49B-11.04B-40.98B-14.88B-15.33B-10.63B-7.34B-8.59B-11.61B-4.28B-4.76B-6.77B-4.75B-1.92B-1.75B-2.42B-1.51B-1.09B-487.2M
CapEx % of Revenue7.77%11.44%8.45%5.88%4.61%8.89%381.15%2.78%4.87%7.78%29.11%9.61%10.34%8.04%6.31%8.87%15.54%6.09%6.86%13.54%7.28%7.89%8.98%12.03%8.39%6.56%4.46%
Acquisitions-2.74B-2.99B-53.41B-12M0-326M-15.51B0536M1.75B-103M-7.94B-276M546M-1.75B1.73B-1.17B-93M-3.17B55.04M84.24M-27.34B-535.68M-9.46M-346.68M49.26M0
Investments---------------------------
Other Investing4.64B1.47B-2.28B-8.16B-6.68B4.19B-1.51B137M1.51B-1.2B672M1.37B989M551M1.17B-1.23B475M387M456M496.68M5.42B-5.56B64.72M-6.16M-97.16M-404.48M75.43M
Cash from Financing3.08B13.4B18.91B-3.76B-26.86B-2.42B-298M-25.16B-21.33B-4.44B-3.69B-17B-4.12B-217M-1.79B3.73B-377M-5.31B-2.53B-6.83B1.76B27.28B1.93B-376.92M-152.56M1.42B-87.35M
Debt Issued (Net)12.6B21.31B23.2B4.35B-20.4B2.73B6.09B-19.16B-15.18B882M-5.22B-11.98B-3.72B3.96B2.29B7.05B8.68B-3.56B-1.79B-7.14B-7.78B27.99B2.36B166.33M38.15M-3.8B46.65M
Equity Issued (Net)426.48M417.73M-1.2B805M368M334M-924M-470M-535M1M-15.69B1M02M1M6M29M17M5M15M10.05B73.83M0-110.76M05.78B0
Dividends Paid-6.64B-7.01B-6.66B-6.65B-4.98B-4.15B-4.15B-3.92B-4B-3.99B-3.39B-4.11B-3.07B-2.98B-2.71B-2.22B-3.06B-1.23B-738M-737.28M-438.54M-437.48M-431.62M-432.54M-190.76M-561.04M-134M
Share Repurchases00-1.39B000-1.19B-474M-535M0-15.69B000000000000-116.23M000
Other Financing-3.31B-1.33B3.57B-2.27B-1.85B-1.34B-1.32B-1.61B-1.61B-1.33B20.61B-1.61B3.19B-1.19B-1.37B-1.11B-6.02B-529M0287K-79.23M-341.1M043.38K-152.87B-48.73K0
Net Change in Cash2.29B-875.84M7.49B1.33B-9.07B32M12.86B-266M-314M-1.24B-1.14B-473M-3.06B3.4B-2.33B1.72B-885M1.17B-1.61B-10.58B14.3B-5.59B4.91B-2.9B2.16B4.63B-78.27M
Free Cash Flow12.01B32.1B12.03B18B40.01B9.06B23.14B23.73B21.21B6.99B-19.47B26.37B9.71B8.84B5.98B7.57B-3.6B8.94B-256M-646.96M7.08B-272.35M542.45M1.59B2.84B3.56B127.67M
FCF Margin %3.63%9.08%3.7%6.45%16.27%4.23%905.51%13.59%13.79%4.92%-13.83%17.05%6.55%6.69%5.14%7.82%-4.82%12.73%-0.37%-1.29%10.86%-1.12%2.79%7.89%15.78%21.43%1.17%
FCF Growth %-34.96%166.85%-33.16%-55.02%341.65%-60.85%-2.46%11.85%203.65%135.88%-173.83%171.71%9.85%47.73%-20.94%310.31%-140.22%3593.36%60.43%-109.13%2701.43%-150.21%-65.82%-44.17%-20.11%2687.35%-
FCF per Share14.4238.5314.4221.5948.0910.8927.8328.5725.538.41-23.3230.8311.3610.357.028.89-4.2310.54-0.30-0.778.90-0.360.712.073.724.670.20
FCF Conversion (FCF/Net Income)0.43x1.26x0.82x0.82x1.31x1.19x153.75x1.53x1.53x1.84x1.79x2.06x1.13x0.90x0.79x1.13x0.73x12.38x-0.87x1.31x1.27x1.01x10.85x1.62x1.24x0.95x0.83x
Interest Paid000000000000000000000000000
Taxes Paid000000000000000000000000000

Key Metrics

Growth RegimeDecelerating
ProfitabilityStrained
Balance SheetHealthy
Cash FlowDeteriorating
Top Statement Risk

Working capital drain undermining cash conversion

Earnings-Cash Gap Widens Sharply

Dr. Reddy's operating cash flow collapsed to negative $927M in 2027Q1 against $4.5B in net income, producing an OCF/NI ratio of -0.21, while cumulative 10-quarter OCF of approximately $87.4B trails cumulative net income of $111.1B by roughly $24B, suggesting structurally accrual-heavy earnings.

The sequential deterioration from an OCF/NI ratio of 6.91 in 2026Q4 to -0.21 in 2027Q1 and then 0.51 in 2027Q2 represents a fundamental breakdown in cash conversion that cannot be explained by seasonality alone. The 2026Q4 spike to 6.91 coincided with a $7.8B working capital release and a $15.4B OCF on only $2.2B of net income, indicating that the reported figure was driven by balance sheet unwinding rather than operating performance. The cumulative gap of approximately 21% between net income and operating cash flow over the 10-quarter window suggests that reported earnings may be persistently overstated relative to realized cash collections, a pattern consistent with aggressive revenue recognition on chargebacks and shelf-stock provisions as flagged in the prior income statement analysis.

FCF Volatility Signals Erosion

Free cash flow has swung from $10.8B in 2025Q4 to negative $4.6B in 2027Q1, with the most recent quarter recovering to only $2.3B at a 2.7% FCF margin, well below the 12.6% margin recorded in 2025Q4, reflecting both working capital consumption and elevated capital expenditure.

The FCF trajectory shows a clear pattern of diminishing quality — the $10.8B FCF in 2025Q4 was inflated by a $584M working capital release and modest capex, while the $10.7B in 2026Q4 similarly benefited from a $7.8B working capital release. Excluding these releases, underlying FCF generation appears materially weaker. The 2027Q1 negative FCF of -$4.6B, driven by a -$12.0B working capital swing combined with $3.4B of capex on only $4.5B of net income, represents a severe cash stress event. While 2027Q2 shows nominal recovery at $2.3B FCF, the 2.7% margin remains depressed relative to the 6-7% range seen in mid-2026, suggesting the trajectory is deteriorating rather than stabilizing.

Working Capital Swings Destabilize Liquidity

Dr. Reddy's working capital consumed $21.9B across 2027Q1 and 2027Q2 combined, reversing a $7.8B release in 2026Q4, with cumulative working capital changes over 10 quarters swinging between -$13.1B and +$7.8B, reflecting severe operational unpredictability in inventory and receivables management.

The magnitude of these working capital swings is extraordinary relative to the company's net income base and suggests that the underlying business is experiencing significant volatility in either collection cycles, inventory positioning, or provisioning dynamics — or some combination thereof. The -$13.1B drain in 2025Q1 followed by -$7.8B in 2025Q2 and then positive $584M in 2025Q4 indicates a business where working capital needs are not predictable on a quarter-to-quarter basis, making cash flow forecasting inherently unreliable. The recent back-to-back drains of -$12.0B and -$9.9B in 2027 align with the revenue contraction noted in the prior income statement analysis, which could suggest receivables buildup from slower-paying US wholesaler channels or inventory accumulation tied to declining sell-through — both warrant further investigation into the company's disclosure of provisions for sales returns and shelf-stock adjustments.

Cumulative Earnings Overstate Cash Reality

Over the 10-quarter period, Dr. Reddy's cumulative net income of approximately $111.1B exceeded cumulative operating cash flow of $87.4B by roughly $23.7B, yielding a cumulative OCF/NI ratio of approximately 0.79 and indicating that the quality of reported earnings has been persistently substandard.

A cumulative OCF/NI ratio below 1.0 across a full cycle is a classic indicator of accrual-based earnings inflation, where revenue is recognized before cash is collected or expenses are deferred. The gap is particularly acute when the $51.8B acquisition in 2025Q2 is excluded from the analysis, as that transaction would have reduced OCF through any associated working capital adjustments. The divergence suggests that the prior income statement analysis finding of gross margin compression to 52.77% may actually understate the economic deterioration, because the cash conversion gap implies that even the compressed reported margins are not fully translating into realized cash. Investors should monitor whether this gap narrows in subsequent quarters; persistent divergence at this magnitude would raise questions about the durability of the reported earnings base.

SBC Inconsistency and D&A-Capex Mismatch Obscure True Economics

Stock-based compensation was reported as $0 in 2027Q2 and 2026Q4 despite $97M to $113M in adjacent quarters, while quarterly depreciation and amortization of $3.8-5.7B consistently exceeds maintenance capex, suggesting the cash flow statement may not fully reflect the economic cost of asset consumption or equity compensation.

The erratic SBC reporting — oscillating between $0 and $113M across quarters — complicates any attempt to construct a clean adjusted cash flow picture, as zero SBC in quarters with $9-15B of net income is difficult to reconcile with a pharmaceutical company's typical equity compensation structure. More significantly, D&A has grown from $3.8B to $5.7B quarterly while capex has been volatile in the $3.4-11.3B range; in quarters where capex falls below D&A (such as 2027Q1 at $3.4B capex vs. $5.4B D&A), the company may be underinvesting in productive capacity relative to asset consumption, which would further erode the quality of future earnings. The $647.8M positive acquisition cash flow in 2027Q2 (indicating asset disposals) alongside a $3.2B acquisition outflow in 2026Q4 suggests portfolio reshuffling that could be generating non-recurring cash inflows masking operational weakness.

RDY — Frequently Asked Questions

Quick answers to the most common questions about buying RDY stock.

How much cash does Dr. Reddy's Laboratories Limited (RDY) generate from operations?

Dr. Reddy's Laboratories Limited (RDY) generated $56.65B in net cash from operating activities in 2026. This reflects the cash generated directly from core business operations.

What is Dr. Reddy's Laboratories Limited's free cash flow?

Dr. Reddy's Laboratories Limited (RDY) generated $32.10B in free cash flow in 2026. Free cash flow is the cash left over after capital expenditures, which can be used to pay dividends, repurchase shares, or pay down debt.

What is Dr. Reddy's Laboratories Limited's capital expenditure (CapEx)?

Dr. Reddy's Laboratories Limited (RDY) spent $40.43B on capital expenditures in 2026. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.

How does Dr. Reddy's Laboratories Limited distribute cash to shareholders?

In 2026, Dr. Reddy's Laboratories Limited (RDY) returned $7.01B to shareholders via cash dividends. This shows the company's commitment to returning capital to its equity investors.